Allergy Therapeutics Stock Surges as FDA Lifts Hold
Shares in Allergy Therapeutics plc surged 36 percent Friday on news that the FDA had finally lifted a five-year clinical hold on the development of its Monophosphoryl Lipid A (MPL)-adjuvanted grass pollen allergy vaccine (Grass MATA MPL/ Pollinex Quattro Grass 0.5ml) and had cleared a Phase III protocol for determining the product's efficacy.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter